vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and CPI Card Group Inc. (PMTS). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $153.1M, roughly 1.8× CPI Card Group Inc.). CPI Card Group Inc. runs the higher net margin — 4.8% vs -45.7%, a 50.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 22.3%). CPI Card Group Inc. produced more free cash flow last quarter ($35.2M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 16.9%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
CPI Card Group Inc. is a leading provider of payment card production and associated solutions, including contactless and contact credit/debit cards, prepaid cards, and card personalization services. It primarily serves financial institutions, fintech firms, and retail brands across its core North American market.
GH vs PMTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $153.1M |
| Net Profit | $-128.5M | $7.3M |
| Gross Margin | 64.6% | 31.5% |
| Operating Margin | -43.0% | 12.0% |
| Net Margin | -45.7% | 4.8% |
| Revenue YoY | 39.4% | 22.3% |
| Net Profit YoY | -15.8% | 8.5% |
| EPS (diluted) | $-1.01 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $153.1M | ||
| Q3 25 | $265.2M | $138.0M | ||
| Q2 25 | $232.1M | $129.8M | ||
| Q1 25 | $203.5M | $122.8M | ||
| Q4 24 | $201.8M | $125.1M | ||
| Q3 24 | $191.5M | $124.8M | ||
| Q2 24 | $177.2M | $118.8M | ||
| Q1 24 | $168.5M | $111.9M |
| Q4 25 | $-128.5M | $7.3M | ||
| Q3 25 | $-92.7M | $2.3M | ||
| Q2 25 | $-99.9M | $518.0K | ||
| Q1 25 | $-95.2M | $4.8M | ||
| Q4 24 | $-111.0M | $6.8M | ||
| Q3 24 | $-107.8M | $1.3M | ||
| Q2 24 | $-102.6M | $6.0M | ||
| Q1 24 | $-115.0M | $5.5M |
| Q4 25 | 64.6% | 31.5% | ||
| Q3 25 | 64.7% | 29.7% | ||
| Q2 25 | 65.0% | 30.9% | ||
| Q1 25 | 63.3% | 33.2% | ||
| Q4 24 | 61.6% | 34.1% | ||
| Q3 24 | 61.1% | 35.8% | ||
| Q2 24 | 59.1% | 35.7% | ||
| Q1 24 | 61.2% | 37.1% |
| Q4 25 | -43.0% | 12.0% | ||
| Q3 25 | -37.3% | 9.4% | ||
| Q2 25 | -45.9% | 7.3% | ||
| Q1 25 | -54.6% | 11.5% | ||
| Q4 24 | -62.4% | 12.7% | ||
| Q3 24 | -61.3% | 14.3% | ||
| Q2 24 | -56.8% | 12.5% | ||
| Q1 24 | -59.2% | 12.6% |
| Q4 25 | -45.7% | 4.8% | ||
| Q3 25 | -35.0% | 1.7% | ||
| Q2 25 | -43.0% | 0.4% | ||
| Q1 25 | -46.8% | 3.9% | ||
| Q4 24 | -55.0% | 5.4% | ||
| Q3 24 | -56.3% | 1.0% | ||
| Q2 24 | -57.9% | 5.1% | ||
| Q1 24 | -68.2% | 4.9% |
| Q4 25 | $-1.01 | $0.62 | ||
| Q3 25 | $-0.74 | $0.19 | ||
| Q2 25 | $-0.80 | $0.04 | ||
| Q1 25 | $-0.77 | $0.40 | ||
| Q4 24 | $-0.90 | $0.56 | ||
| Q3 24 | $-0.88 | $0.11 | ||
| Q2 24 | $-0.84 | $0.51 | ||
| Q1 24 | $-0.94 | $0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $21.7M |
| Total DebtLower is stronger | $1.5B | $286.7M |
| Stockholders' EquityBook value | $-99.3M | $-17.3M |
| Total Assets | $2.0B | $403.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $21.7M | ||
| Q3 25 | $580.0M | $16.0M | ||
| Q2 25 | $629.1M | $17.1M | ||
| Q1 25 | $698.6M | $31.5M | ||
| Q4 24 | $525.5M | $33.5M | ||
| Q3 24 | $585.0M | $14.7M | ||
| Q2 24 | $933.7M | $7.5M | ||
| Q1 24 | $1.0B | $17.1M |
| Q4 25 | $1.5B | $286.7M | ||
| Q3 25 | $1.1B | $308.4M | ||
| Q2 25 | $1.1B | $310.9M | ||
| Q1 25 | $1.1B | $280.7M | ||
| Q4 24 | $1.1B | $280.4M | ||
| Q3 24 | — | $280.2M | ||
| Q2 24 | — | $269.7M | ||
| Q1 24 | — | $265.3M |
| Q4 25 | $-99.3M | $-17.3M | ||
| Q3 25 | $-354.5M | $-25.7M | ||
| Q2 25 | $-305.5M | $-29.0M | ||
| Q1 25 | $-250.8M | $-29.7M | ||
| Q4 24 | $-139.6M | $-35.6M | ||
| Q3 24 | $-60.1M | $-42.8M | ||
| Q2 24 | $-1.6M | $-44.6M | ||
| Q1 24 | $68.3M | $-48.5M |
| Q4 25 | $2.0B | $403.2M | ||
| Q3 25 | $1.3B | $407.1M | ||
| Q2 25 | $1.3B | $399.8M | ||
| Q1 25 | $1.3B | $351.9M | ||
| Q4 24 | $1.5B | $349.7M | ||
| Q3 24 | $1.5B | $342.3M | ||
| Q2 24 | $1.6B | $321.4M | ||
| Q1 24 | $1.7B | $319.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $39.6M |
| Free Cash FlowOCF − Capex | $-54.2M | $35.2M |
| FCF MarginFCF / Revenue | -19.3% | 23.0% |
| Capex IntensityCapex / Revenue | 9.9% | 2.9% |
| Cash ConversionOCF / Net Profit | — | 5.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $41.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $39.6M | ||
| Q3 25 | $-35.4M | $10.0M | ||
| Q2 25 | $-60.3M | $4.3M | ||
| Q1 25 | $-62.7M | $5.6M | ||
| Q4 24 | $-64.5M | $26.7M | ||
| Q3 24 | $-51.1M | $12.5M | ||
| Q2 24 | $-94.0M | $-4.8M | ||
| Q1 24 | $-30.3M | $8.9M |
| Q4 25 | $-54.2M | $35.2M | ||
| Q3 25 | $-45.8M | $5.3M | ||
| Q2 25 | $-65.9M | $533.0K | ||
| Q1 25 | $-67.1M | $292.0K | ||
| Q4 24 | $-83.4M | $21.6M | ||
| Q3 24 | $-55.3M | $11.1M | ||
| Q2 24 | $-99.1M | $-6.0M | ||
| Q1 24 | $-37.2M | $7.4M |
| Q4 25 | -19.3% | 23.0% | ||
| Q3 25 | -17.3% | 3.8% | ||
| Q2 25 | -28.4% | 0.4% | ||
| Q1 25 | -33.0% | 0.2% | ||
| Q4 24 | -41.3% | 17.3% | ||
| Q3 24 | -28.9% | 8.9% | ||
| Q2 24 | -55.9% | -5.0% | ||
| Q1 24 | -22.1% | 6.6% |
| Q4 25 | 9.9% | 2.9% | ||
| Q3 25 | 3.9% | 3.4% | ||
| Q2 25 | 2.4% | 2.9% | ||
| Q1 25 | 2.2% | 4.3% | ||
| Q4 24 | 9.4% | 4.0% | ||
| Q3 24 | 2.2% | 1.2% | ||
| Q2 24 | 2.9% | 1.0% | ||
| Q1 24 | 4.1% | 1.3% |
| Q4 25 | — | 5.39× | ||
| Q3 25 | — | 4.32× | ||
| Q2 25 | — | 8.39× | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | 3.94× | ||
| Q3 24 | — | 9.70× | ||
| Q2 24 | — | -0.79× | ||
| Q1 24 | — | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PMTS
| US Debit And Credit | $128.9M | 84% |
| US Prepaid Debit | $24.4M | 16% |
